Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGTNASDAQ:RDNTNASDAQ:VCYTNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$20.12+2.1%$17.87$14.57▼$25.11$612.53M1270,379 shs406,012 shsRDNTRadNet$57.03+2.3%$50.85$45.00▼$93.65$4.28B1.46671,070 shs1.15 million shsVCYTVeracyte$30.76+3.5%$31.00$19.73▼$47.32$2.33B2.14882,049 shs1.08 million shsVRDNViridian Therapeutics$13.12+5.9%$13.66$9.90▼$27.20$1.07B0.571.19 million shs942,955 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+2.92%+2.86%+5.89%+23.66%-7.49%RDNTRadNet+2.26%+7.34%+6.78%-7.69%+3.22%VCYTVeracyte+4.73%-1.79%-3.27%-24.92%+43.94%VRDNViridian Therapeutics+4.63%0.00%+9.15%-26.54%-5.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics3.3829 of 5 stars2.31.00.04.12.14.20.6RDNTRadNet3.4376 of 5 stars2.71.00.04.63.32.50.0VCYTVeracyte3.8902 of 5 stars4.41.00.04.32.20.00.6VRDNViridian Therapeutics1.5217 of 5 stars4.50.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.50Moderate Buy$24.0019.28% UpsideRDNTRadNet 3.40Buy$69.7522.30% UpsideVCYTVeracyte 2.70Moderate Buy$40.9032.96% UpsideVRDNViridian Therapeutics 2.91Moderate Buy$36.70179.73% UpsideCurrent Analyst Ratings BreakdownLatest RDNT, VCYT, VRDN, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $27.005/7/2025VRDNViridian TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.005/7/2025VRDNViridian TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.005/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $36.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.004/23/2025VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $34.004/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.004/9/2025VCYTVeracyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $37.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$292.45M2.09$3.93 per share5.12$38.24 per share0.53RDNTRadNet$1.83B2.34$3.03 per share18.81$11.79 per share4.84VCYTVeracyte$463.39M5.20$0.07 per share442.29$14.30 per share2.15VRDNViridian Therapeutics$302K3,544.66N/AN/A$4.48 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%8/1/2025 (Estimated)RDNTRadNet$3.04M$0.03N/A107.60N/A-0.25%4.29%1.45%N/AVCYTVeracyte-$74.40M$0.41N/A42.72N/A-2.18%3.02%2.80%N/AVRDNViridian Therapeutics-$237.73M-$3.85N/AN/AN/A-85,127.16%-70.12%-41.49%5/14/2025 (Estimated)Latest RDNT, VCYT, VRDN, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VRDNViridian Therapeutics-$0.95N/AN/AN/A$0.04 millionN/A5/6/2025Q1 2025VRDNViridian Therapeutics-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million2/27/2025Q4 2024RDNTRadNet$0.21$0.22+$0.01$0.07$459.42 million$477.10 million2/27/2025Q4 2024VRDNViridian Therapeutics-$1.05-$0.81+$0.24-$0.81$0.05 million$0.07 million2/24/2025Q4 2024VCYTVeracyte$0.29$0.36+$0.07$0.06$110.73 million$118.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A4.414.41RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79VRDNViridian Therapeutics0.0418.5518.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%RDNTRadNet77.90%VCYTVeracyteN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics31.76%RDNTRadNet5.12%VCYTVeracyte1.30%VRDNViridian Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,01030.44 million20.87 millionOptionableRDNTRadNet8,97075.01 million70.24 millionOptionableVCYTVeracyte79078.31 million76.49 millionOptionableVRDNViridian Therapeutics5081.59 million78.70 millionOptionableRDNT, VCYT, VRDN, and FLGT HeadlinesRecent News About These CompaniesViridian Therapeutics (VRDN) to Release Earnings on WednesdayMay 13 at 1:31 AM | americanbankingnews.comB. Riley Lifts Earnings Estimates for Viridian TherapeuticsMay 11 at 8:12 AM | marketbeat.comHC Wainwright Analysts Cut Earnings Estimates for VRDNMay 11 at 8:12 AM | marketbeat.comQ2 EPS Estimate for Viridian Therapeutics Cut by AnalystMay 11 at 8:12 AM | marketbeat.comQ2 EPS Forecast for Viridian Therapeutics Boosted by AnalystMay 11 at 8:11 AM | marketbeat.comDriehaus Capital Management LLC Decreases Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 11 at 6:48 AM | marketbeat.comB. Riley Analysts Boost Earnings Estimates for VRDNMay 11 at 1:40 AM | americanbankingnews.comQ2 EPS Forecast for Viridian Therapeutics Lowered by AnalystMay 11 at 1:09 AM | americanbankingnews.comWedbush Brokers Increase Earnings Estimates for VRDNMay 11 at 1:09 AM | americanbankingnews.comQ1 Earnings Forecast for VRDN Issued By HC WainwrightMay 10 at 8:55 AM | marketbeat.comConcentric Capital Strategies LP Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 10 at 6:29 AM | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Given New $27.00 Price Target at The Goldman Sachs GroupMay 10 at 2:19 AM | americanbankingnews.comRoyal Bank of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock PriceMay 10 at 2:19 AM | americanbankingnews.comHC Wainwright Has Negative Outlook for VRDN Q2 EarningsMay 10 at 1:21 AM | americanbankingnews.comVeligrotug receives breakthrough therapy designation for thyroid eye diseaseMay 9, 2025 | healio.comNeedham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00May 9, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) is Deep Track Capital LP's 9th Largest PositionMay 9, 2025 | marketbeat.comViridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comCrestline Management LP Purchases 48,315 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 9, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VRDN Q1 Earnings?May 9, 2025 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $36.00 by Analysts at Needham & Company LLCMay 9, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDNT, VCYT, VRDN, and FLGT Company DescriptionsFulgent Genetics NASDAQ:FLGT$20.12 +0.42 (+2.13%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$20.82 +0.70 (+3.46%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.RadNet NASDAQ:RDNT$57.03 +1.29 (+2.31%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$55.86 -1.17 (-2.05%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$30.76 +1.05 (+3.53%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$30.23 -0.53 (-1.72%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Viridian Therapeutics NASDAQ:VRDN$13.12 +0.73 (+5.89%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$13.00 -0.12 (-0.91%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
